DTIL (Precision BioSciences) LT-Debt-to-Total-Asset : 0.19 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Precision BioSciences's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.19.

Precision BioSciences's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.19). It may suggest that Precision BioSciences is progressively becoming more dependent on debt to grow their business.

Precision BioSciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Precision BioSciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences LT-Debt-to-Total-Asset Chart

Precision BioSciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.03

0.10

0.05

Precision BioSciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.05	0.04	0.04	0.19

Precision BioSciences LT-Debt-to-Total-Asset Calculation

Precision BioSciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	7.723	/	159.781
	=	0.05

Precision BioSciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	29.032	/	153.258
	=	0.19

Precision BioSciences (NAS:DTIL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Precision BioSciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Precision BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

PBS0:Germany

Address

302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701

Website

https://www.precisionbiosciences.com

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Executives

J. Jefferson Smith	10 percent owner	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Dario Scimeca	officer: General Counsel	C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Michael Amoroso	director, officer: President and CEO	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Kevin Buehler	director	C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly	officer: Interim CFO	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Melinda Brown	director	10 HUDSON YARDS, NEW YORK NY 10001
Alan List	officer: Chief Medical Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056
Pharma Ag Novartis	10 percent owner	LICHTSTRASSE 35, CH-4002, BASEL V8
Derek Jantz	director, 10 percent owner, officer: Chief Scientific Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shari Lisa Pire	director	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson	officer: Chief Development Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Matthew R. Kane	director, 10 percent owner, officer: President and CEO	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701